학술논문
Circulating levels and prognostic cut‐offs of sST2, hs‐cTnT, and NT‐proBNP in women vs. men with chronic heart failure
Document Type
article
Author
Giuseppe Vergaro; Francesco Gentile; Alberto Aimo; James L. Januzzi Jr; A. Mark Richards; Carolyn S.P. Lam; Rudolf A. deBoer; Laura M.G. Meems; Roberto Latini; Lidia Staszewsky; Inder S. Anand; Jay N. Cohn; Thor Ueland; Lars Gullestad; Pål Aukrust; Hans‐Peter Brunner‐La Rocca; Antoni Bayes‐Genis; Josep Lupón; Akiomi Yoshihisa; Yasuchika Takeishi; Michael Egstrup; Ida Gustafsson; Hanna K. Gaggin; Kai M. Eggers; Kurt Huber; Greg D. Gamble; Lieng H. Ling; Kui Toh Gerard Leong; Poh Shuah Daniel Yeo; Hean Yee Ong; Fazlur Jaufeerally; Tze P. Ng; Richard Troughton; Robert N. Doughty; Gerry Devlin; Mayanna Lund; Alberto Giannoni; Claudio Passino; Michele Emdin
Source
ESC Heart Failure, Vol 9, Iss 4, Pp 2084-2095 (2022)
Subject
Language
English
ISSN
2055-5822
Abstract
Abstract Aims To define plasma concentrations, determinants, and optimal prognostic cut‐offs of soluble suppression of tumorigenesis‐2 (sST2), high‐sensitivity cardiac troponin T (hs‐cTnT), and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) in women and men with chronic heart failure (HF). Methods and results Individual data of patients from the Biomarkers In Heart Failure Outpatient Study (BIOS) Consortium with sST2, hs‐cTnT, and NT‐proBNP measured were analysed. The primary endpoint was a composite of 1 year cardiovascular death and HF hospitalization. The secondary endpoints were 5 year cardiovascular and all‐cause death. The cohort included 4540 patients (age 67 ± 12 years, left ventricular ejection fraction 33 ± 13%, 1111 women, 25%). Women showed lower sST2 (24 vs. 27 ng/mL, P